Haig Aghajanian

Founder of Capstan Therapeutics, UPenn Department of Medicine

[Haig Aghajanian @Haig_Ag]

Very excited to be a part of this fantastic collaboration and share this study with everybody. I hope this brings us a step closer to addressing the enormous burden of cardiac and other fibrotic diseases.

[Jon Epstein Lab @JonEpsteinLab]

Thank you to the whole team (including those not on Twitter!)
First Author: @DevBioAcademic
Co-corresponding: @WeissmanLab, Hamideh Parhiz, @Haig_Ag, & @jonepstein1
Collaborators at @AcuitasTx, @carlhjune, and many others.

6/6

[Nature Biotechnology @NatureBiotech]

In vivo CAR-Ts captivate big pharma https://t.co/Ze96LtrsvO

[Science Magazine @ScienceMagazine]

In Science, researchers present a new method to safely and preferentially generate CAR T cells directly inside the body using targeted lipid nanoparticles that deliver mRNA directly to T cells.

The approach showed rapid and sustained immune reprogramming in preclinical models, highlighting its promise for treating cancer and autoimmune diseases.

📄: https://t.co/MYtLr1j3q2
#SciencePerspective: https://t.co/vcaXeCQ5vs

[Nature Metabolism @NatMetabolism]

🏆 Best of #NatMetab2022 | CITATIONS
#14

The @JonEpsteinLab (@PennMedicine) summarize ongoing developments of CAR-based therapies for indications beyond #cancer, including for cardiometabolic diseases, fibrosis, autoimmune diseases & aging.

https://t.co/Ppr4Mqfsqz

[Lee Cooper @leecoo4]

“CAR-T made entirely within the body”

Lots of good work ahead to make this a reality! @capstantx @lshawverO @BLLPHD @Haig_Ag
https://t.co/MuGET7udW8

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

@NEJM Fighting Cardiac Fibrosis with CAR T Cells- Clinical Implications of Basic Research "An advance for several reasons" 1) off the shelf CAR T cells 2) transient expression 3) remarkable lipid nanoparticle safety record @PennMedicine @WeissmanLab ⁦
@JonEpsteinLab @carlhjune

[Nature Metabolism @NatMetabolism]

PERSPECTIVE | Aghajanian, Rurik & @JonEpsteinLab (@PennMedicine) summarize the ongoing development of CAR-based therapies for indications beyond cancer, including for cardiometabolic diseases, fibrosis, autoimmune diseases & aging. #immunotherapy

https://t.co/Ppr4Mqx3P9

[Controlled Release Society @CRSScience]

We are excited to announce 3 new speakers at our LNP-RNA Therapeutics Beyond COVID Virtual Symposium!

Meet Philip Robert from CPI, Adrian Abbotts from @Siemens & @Haig_Ag from @Penn

Click here to register for the 2-Day virtual event: https://t.co/YyRfTgDzdX

[Ron Vagnozzi @VagnozziRJ]

Merging RNA technology and #cardioimmunology to tackle heart fibrosis - some thoughts from @McKinseyLab and us on this exciting new approach by @JonEpsteinLab & colleagues. Check out the full paper at https://t.co/CL5yb7ujWh #CardioTwitter

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

🆕Review: CAR-based therapies: opportunities for immuno-medicine beyond cancer- by Haig Aghajanian, @DevBioAcademic, @jonepstein1 #immunotherapy @NatMetabolism https://t.co/4ifO9WL5h6

[Haig Aghajanian @Haig_Ag]

@jonepstein1 Thanks Jon! The potential of CAR T cell therapy is almost endless. Very exciting!

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

🚨New: Decade-long #leukemia remissions with persistence of CD4+ CAR T-cells demonstrates long-term potential and clonal stability of #CARTCell therapy #tcell #tcellrx #cancer #immunotherapy @PennMedicine @Nature Portfolio https://t.co/HESZzOT1DZ

[Twist Bioscience @TwistBioscience]

Researchers @DevBioAcademic @Haig_Ag @WeissmanLab @jonepstein1 and team harnessed #mRNA tech to create therapeutic CAR-T cells (in mice) to treat heart disease.

mRNA shot spawns CAR-T cells in the body to repair heart disease damage | FierceBiotech https://t.co/R4Lrka5b4s

[Seth Thomas Scanlon @ImmunoEditor]

In this week's @ScienceMagazine cover story, @DevBioAcademic, @Haig_Ag, @WeissmanLab, Parhiz, @JonEpsteinLab, & al. use CD5-targeted lipid #nanoparticles to generate therapeutic #CARTcells in vivo!

https://t.co/H4v842s8Kq

w/ PS by Gao & Chen:

https://t.co/mOGC8NhuXA

[The Scientist @TheScientistLLC]

JUST OUT: New, off-the-shelf method for generating CAR T cells in vivo developed and tested in mice. https://t.co/CzaS1dm1cL

[FierceBiotech @FierceBiotech]

An experimental #mRNA therapy makes CAR-T cells inside the body to target heart fibrosis. The @PennMedicine study marks an important step in developing accessible and affordable "off-the-shelf" personalized immunotherapies. https://t.co/eW78l1Ihsg

[Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉 @BLLPHD]

#CARTCell Principal Scientist #hiring at Capstan Therapeutics- responsible for setting up and executing on a robust preclinical CAR T program with applications in multiple disease categories, cell types, and indications. https://t.co/XgUa4F7mKD

[Haig Aghajanian @Haig_Ag]

Well deserved.

[The Nobel Prize @NobelPrize]

BREAKING NEWS:
The 2021 #NobelPrize in Physiology or Medicine has been awarded jointly to David Julius and Ardem Patapoutian “for their discoveries of receptors for temperature and touch.”

[Haig Aghajanian @Haig_Ag]

Maybe this hidden gem is not so hidden anymore...

[Michael Alexanian @m_alexanian]

Our work “A transcriptional switch governs fibroblast activation in heart disease” previously on @biorxivpreprint is now online @Nature. A great team effort @GladstoneInst @dsrivastava_md and all the fantastic collaborators. A new thread /1 👇
https://t.co/leqLScOyLG